InvestorsHub Logo

Doktornolittle

03/27/15 11:07 AM

#3771 RE: dakota #3770

I'm out. I do believe this is the second conference in a row where they advertised an appearance and an archived webcast... and then just didn't show.

That alone might not spook me, but as I recall, there was never any explanation last time, and so far, no explanation this time. For there to be no explanation is UFB! Who are these people? I had such a positive impression of them based on other info. But I am out.

I don't care about sloppy so much, as the product matters more to me. But this is not sloppy. To have no comment after two no-shows in a row is ominous.

That and the fact that neither of their current trials appears to involve the highly touted TAP technology. And the fact that the number of outstanding shares is awfully high for a company this early in development. The number of shares per se actually doesn't matter... sort of, just as the SP doesn't matter, sort of... the market cap is really what matters... sort of. But the number of outstanding shares is so much higher than I thought it was that the cap is therefore much higher than I thought it was... and the number of outstanding shares does matter some because there are SP thresholds... $1 to get listed, and $4 for many firms to be allowed to buy the stock. So when you generate that many shares outstanding it becomes that much more difficult to reach those magic thresholds of $1 and $4 due to the required capitalization / market cap.

dayneyus

03/28/15 12:58 PM

#3772 RE: dakota #3770

I viewed the presentations. It is likely he was their to network with the presenting companies as their platforms may benefit from TPIV's platform. Both companies are working at activating immune cells right up on track with TPIV's goals.